Fig. 2From: Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myelomaTornado diagram. The green bar section representing the parameter range from the low uncertainty value to the base case, while the orange bar section represents the parameter range from the base case to the high uncertainty value. DAR Daratumumab, CAR Carfilzumib, P probability, U utility, PFS progression-free survival, C cost, PS progression stateBack to article page